---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-001482"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2026-08-13T20:31:12+00:00"
generated_at: "2026-08-13T20:34:09.321696+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vivani Q2 net loss $6.4M; SLIM-1 fully enrolled; Novo Nordisk deal; Cortigent merger on track

## Summary
- Q2 2026 net loss $6.4M vs $7.1M in Q2 2025; cash $20.8M at June 30, 2026.
- SLIM-1 Phase 1 trial of NPM-139 fully enrolled (20 participants); top-line data expected November 2026.
- Non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant; no exclusivity provisions.
- Cortigent merger with ClearOne expected to close Q3 2026; post-merger company to trade as CRGT on Nasdaq.
- August J. Moretti appointed to board; former CFO of 4D Molecular Therapeutics.

## SEC filing metadata
- accession: 0001753926-26-001482
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2026-08-13T20:31:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001482/0001753926-26-001482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001482/vani-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-001482
- JSON: https://secwatch.observer/filing/0001753926-26-001482.json
- Plain text: https://secwatch.observer/filing/0001753926-26-001482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.